As you browse our test menu, and you see your preferred test, simply select the Add to Favorites button. Sensitivity and specificity of the results have made this antibody a useful tool in the screening of patients…, RT-PCR and sequencing of the BCR-ABL1 fusion transcript for qualitative detection of mutations associated with resistance to Gleevec (imatinib) and other tyrosine kinase inhibitors. The all-time high NeoGenomics stock closing price was 43.94 on October 15, 2020.; The NeoGenomics 52-week high stock price is 44.58, which is 3.9% above the current share price. Special stain. This suggests that the stock has a possible downside of 14.7%. Disease(s): Anaplastic large cell lymphoma, NHL, Probes: ALK (2p23) This add-on panel is available to clarify findings on samples currently having flow cytometry analysis at NeoGenomics and is not available for stand-alone testing. NeoGenomics Price to Book Value: 5.923 for June 3, 2020. Shares of NeoGenomics soared over 11% today after the company reported third-quarter 2019 operating results. Disease(s): Acute lymphoblastic (lymphocytic)…, Available as global and tech-only. NEO: Get the latest Neogenomics stock price and detailed information including NEO news, historical charts and realtime prices. View analysts' price targets for NeoGenomics. New Tests. NeoGenomics has converted a portion of its lab space to run up to 10,000 SARS-CoV-2 diagnostic tests per day, which could increase in the future. Markers are cCD3, cCD22, cCD79, CD11b, CD123, CD34… NeoGenomics Inc’s share price is determined by its bid-ask spread, which is the difference between the price that buyers are willing to pay and the price that sellers are willing to accept. Consolidated operating expenses increased by $3.5 million, or 13%, from Quarter 2 2016, primarily as a result of increased payroll, depreciation, non-cash stock-based compensation, and bad debt expenses. Sorry for the convenience. Benchmark’s target price would indicate a potential upside of 16.36% from the company’s previous close. Sorry for the convenience. Clarient, a unit of GE Healthcare’s Life Sciences business that does cancer diagnostic … , and has now gained 4 days in a row.It will be exciting to see whether it manages to continue gaining or take a minor break for the next few days. Disease(s): Acute lymphoblastic (lymphocytic) leukemia (B-cell ALL), B…, Probes: PDGFRb (5q32), BCR/ABL1-ASS1 t(9;22), JAK2 (9p24.1), EPOR (19p13.2) and CRLF2 (Xp22.33/Yp11.32) are included in the ALL FISH (Ph-like) Panel. NeoGenomics (NASDAQ:NEO) had its price objective lifted by analysts at Benchmark from $40.00 to $48.00 in a research report issued on Wednesday, Benzinga reports. Probes: RUNX1/RUNX1T1 (ETO/AML1) t(8;21) | PML/RARA t(15;17) | CBFB inv(16), t(16;16) Probes: 1p36/1p12/1q25 |19q13/19q11q12/19p13 In depth view into NeoGenomics Cost of Goods Sold (Quarterly) including historical data from 1999, charts, stats and industry comps. "We believe NeoGenomics is exceptionally well positioned as we move into 2016," he said. Third Quarter 2017 Highlights: 17% increase in clinical genetic testing volume (1); 4% increase in consolidated revenue to $63.1 million Disease(s): Follicular Lymphoma (FL), Alpha-1-Antitrypsin (AAT) is useful in the study of inherited AAT deficiency, benign and malignant hepatic tumors and yolk sac carcinoma. This suggests that the stock has a possible downside of 14.7%. NeoGenomics stock is the IBD Stock Of The Day as the cancer-testing outlet breaks out on a never-higher relative strength line.. X. NeoGenomics will commercialize the InVisionFirst-Lung liquid biopsy test in the United States . Their forecasts range from $14.50 to $50.00. Probes may be ordered separately. Importantly, test volume in our core clinical (1) oncology business continued to trend higher on what looks to be a V-Shaped recovery and the majority of our pharma clients' clinical trial sites are now open," said Douglas M. VanOort, Chairman and CEO of NeoGenomics. Test Description The NeoTYPE Liver/Biliary Tumor Profile analyzes 38 biomarkers through a combination of next-generation sequencing (NGS), FISH, and IHC as listed below. Disease(s): Non-small cell lung carcinoma (NSCLC). T: 239.768.0600 NEOGENOMICS, INC. () : Stock quote, stock chart, quotes, analysis, advice, financials and news for share NEOGENOMICS, INC. | Boerse Stuttgart: NG9 | Boerse Stuttgart Test orders include summary interpretation of all results to help guide treatment decisions. The test is called a "companion" diagnostic because it aims to detect mutations and provide patients quick access to Piqray, a recently approved drug targeting PIK3CA from Novartis. NEW YORK (GenomeWeb) – NeoGenomics said after the close of the market on Tuesday that is has priced its previously announced underwritten public offering of 7 million shares of its common stock at a public offering price of $21.25 per share.. "Our core business is strong, we expect modest price-per-test … NeoGenomics Reports 15% Volume Growth and 10% Reduction in Average Cost per Test in the First Quarter of 2017 PRESS RELEASE Marketwired Apr. They induce latent infections in tonsils, adenoids and other lymphoid tissue of man, causing either unapparent or limited illnesses that are followed by complete…, Special stain. Browse... View Full Chart Price to Book Value Chart . Probes may be ordered separately except +8 and…. Shares Out 103.35M. The business offers a comprehensive menu of laboratory tests doctors typically use to diagnose, monitor, and assess the … Test Updates . NeoGenomics is a leading provider of cancer-focused genetic testing services in the United States, providing excellence in diagnostic, prognostic, and predictive testing. Gross proceeds to NeoGenomics from the offering are expected to be $148.8 million. Bayer will cover the full cost of the test regardless of the test results, treatment decision and patient’s insurance coverage for up to 500 patients in the U.S. Bayer will not cover the associated costs of extracting a viable tumor specimen. nCounter PanCancer Immune Profiling Panel, DNA Hybridization Capture Target Enrichment, Medical Necessity for BCR-ABL Negative Myeloproliferative Disease, Medical Necessity for NRAS Genetic Testing, Medical Necessity for Next-Generation Sequencing (NGS) for Myeloid and Suspected Myeloid Malignancies, Medical Necessity for Next-Generation Sequencing (NGS) for Solid Tumors, Prior Authorization Insurance Plans and CPT Codes, Precision Medicine in the COVID-19 Crisis. Share price has grown by more than 50% since November to a current high of $29.84. Find the latest NeoGenomics, Inc. (NEO) stock quote, history, news and other vital information to help you with your stock trading and investing. Average cost-of-goods-sold per clinical genetic test ("Cost per Test") declined by 10% compared to the first quarter of 2016, which led to a slight improvement in gross margin for this business. The Company provides one of the most comprehensive oncology-focused testing menus in … To have a better experience, please upgrade to Microsoft Edge, Google Chrome, or Firefox. The list price of a Covid-19 diagnostic test varies widely depending on the hospital, according to a Kaiser Family Foundation analysis released Wednesday. Stock analysis for NeoGenomics Inc (NEO:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile. The… The Company provides one of the most comprehensive oncology-focused testing menus in the world for physicians to help them diagnose and treat cancer. Disease(s): B-cell non-Hodgkin lymphoma. In depth view into NeoGenomics Year to Date Price Returns (Daily) including historical data from 1999, charts, stats and industry comps. On average, they anticipate NeoGenomics' share price to reach $40.95 in the next twelve months. It boasts 10 global locations, serves 2,600 hospitals, and processes 1 million tests annually. The NeoTYPE Bayer today announced the launch of Test4TRK™ program in collaboration with NeoGenomics, Inc. to offer genomic cancer testing for NTRK gene fusions at no cost for patients with RAI-refractory (RAI-R) differentiated thyroid carcinoma (DTC) and metastatic colorectal cancer (mCRC) with high microsatellite instability (MSI-H). X When looking for the best stocks to buy and watch , be sure to pay attention to relative price strength. LabCorp's test menu provides a comprehensive list of specialty and general laboratory testing services. FT. MYERS, FL -- (Marketwired) -- 10/25/17 -- NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, today reported its results for the third quarter of 2017. Send me real-time posts from this site at my email . The ALK1 (ALK1 cline) antibody labels normal human ALK protein and the NPM-ALK chimeric protein, and is a useful tool for the identification of the subgroup of anaplastic large-cell lymphomas (ALCL) that are ALK positive. Bloomberg the Company & Its Products The Company & its Products Bloomberg Terminal Demo Request Bloomberg Anywhere Remote Login Bloomberg Anywhere Login Bloomberg Customer Support Customer Support It operates through the Clinical Services and Pharma Services segments. If you delete your browser cookies, you will need to rebuild your test list. For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide . FORT MYERS, FL / ACCESSWIRE / October 29, 2019 / NeoGenomics, Inc. (NASDAQ: ... Average cost of goods sold per clinical test ("cost per test") increased by … Fort Myers, FL 33913 NTRK gene fusions, which have been shown to drive tumor … NeoGenomics Slumps in Q2 but Readies for Second-Half Rebound The oncology reference lab never stopped investing in near- and long-term opportunities. View 4,000+ financial data types. NeoGenomics is a pure-play oncology reference lab. This add-on panel is available to clarify findings on samples currently having flow cytometry analysis at NeoGenomics and is not available for stand-alone testing. It reacts with ACTH-producing cells (corticotrophs). Flow Cytometry. FT. MYERS, FL / ACCESSWIRE / June 29, 2020 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services, announced … Probes: TNFRSF14 (1p36) The Clinical Services segment offers cancer testing services to community-based pathologists, hospitals, academic centers, and oncology groups. Their forecasts range from $14.50 to $50.00. NEW YORK – Bayer and NeoGenomics on Tuesday launched Test4TRK, a program offering no-cost NTRK gene fusion testing to patients with RAI-refractory differentiated thyroid cancer and metastatic colorectal cancer with high microsatellite instability. Gross margin declined to 43.7%, primarily due to higher average cost per test of Clinical Services and the timing of Pharma Services revenue. ET by Tomi Kilgore Like Amazon, these stocks have 100% buy ratings from analysts Bi-directional Sanger sequencing of ALK is performed using PCR primers designed to target hotspot mutations in exons 23 and 25. NeoGenomics is a leading oncology genetics reference lab. Clients who decline full phenotyping and…, Probes: RPN1, MECOM (3q21, 3q26.2) | 5q-, -5 (5p15, 5q31, 5q33 | 7q-, -7 (Cen 7, 7q22, 7q31) | Trisomy 8 (Cen 8) | DEK/NUP214 (CAN) t(6;9) | MLL (11q23) | ETV6 (12p13) | 17p- (TP53 17p13.1, NF1 17q11.2) | Probes may be ordered separately. About Genomic Cancer Testing Subscribe to this site. The Company provides one of the most comprehensive oncology-focused testing menus in the world for physicians to help them diagnose and treat cancer. View today's stock price, news and analysis for NeoGenomics Inc. (NEO). Available as global and tech-only. VENTANA FDA approved ALK (D5F3) CDx Assay is intended for the qualitative detection of the anaplastic lymphoma kinase (ALK) protein in formalin-fixed, paraffin-embedded (FFPE) non-small cell lung carcinoma (NSCLC) tissue stained with a BenchMark XT…, Probes: ALK (2p23) Gross profit decreased slightly by $0.7 million, or 1.6%, compared to the first quarter of 2019, to $46.4 million. NEO | Complete NeoGenomics Inc. stock news by MarketWatch. NeoGenomics, Inc. specializes in cancer genetic testing and information services. Analysis includes detection of all mutations recommended by…, Anti-adrenocorticotropic hormone (ACTH) is a useful marker in the classification of pituitary tumors and the study of pituitary disease. 10 Wall Street analysts have issued twelve-month price objectives for NeoGenomics' shares. Most non-seminomatous germ cell tumors produce…, Albumin RNA ISH is a sensitive and specific tool for distinguishing primary hepatocellular carcinoma and intrahepatic cholangiocarcinoma from metastatic adenocarcinoma to the liver or carcinoma of unknown origin in formalin fixed paraffin-embedded…. NOTE: This is a cookie-based feature. Acquisition of Genoptix in Dec 2018 has led to 15% increase in revenue per test to $369. Disease(s…, Probes: 5q-, -5 (5p15, 5q31, 5q33) | 7q-, -7 (Cen 7, 7q22, 7q31) | Trisomy 8 (Cen 8) | MLL (11q23) | 20q- (20q12, 20qter) | RUNX1/RUNX1T1 (ETO/AML1) t(8;21) | PML/RARA t(15;17) | CBFB inv(16), t(16;16) View real-time stock prices and stock quotes for a full financial overview. Last Price $47.58 NASDAQ Closing Price as of 3:59PM ET 11/30/20 Disease(s): Oligodendroglioma The company, which … NeoGenomics stock price target raised to $48 from $40 at Benchmark Oct. 28, 2020 at 6:13 a.m. 37% Increase in Pharma Services Revenue. Bayer will cover the full cost of the test regardless of the test results, treatment decision and patient’s insurance coverage for up to 500 patients in the U.S. Bayer will not cover the associated costs of extracting a viable tumor specimen. Neogenomics Inc NEO:NASDAQ. This assay employs one centromeric probe and two distal probes per chromosome to detect and differentiate whole-arm vs partial 1p and 19q deletions, and to detect polysomy. Ft. Myers, Florida – December 10, 2018 – NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, announced today that it has completed the acquisition of the parent company of Genoptix, Inc. for $125 million in cash, as adjusted by working capital and other adjustments, and 1 million shares of NeoGenomics common stock. NEW YORK – Bayer and NeoGenomics on Tuesday launched Test4TRK, a program offering no-cost NTRK gene fusion testing to patients with RAI-refractory differentiated thyroid cancer and metastatic colorectal cancer with high microsatellite instability. The latest closing stock price for NeoGenomics as of November 10, 2020 is 42.90.. Probes: CEN 11 (11p11.1-q11) | MLL (11q23) | 11qTel (11q25) Call the NeoGenomics Client Services team at 866.776.5907 and press 3 to order test requisitions and kits, or to inquire about setting up online ordering through NeoLINK® Disease(s): Philadelphia chromosome (Ph-like) acute lymphoblastic…, Probes: TCF3/PBX1 (E2A/PBX1) t(1;19) | Trisomy or Tetrasomy 4, 6, 10, 17 (Cen 4, Cen 6, Cen 10, Cen 17) | MYC (8q24) | BCR/ABL1/ASS1 t(9;22) | MLL (11q23) | ETV6/RUNX1 (TEL/AML1) t(12;21) | IgH (14q32) NeoGenomics just hit that mark, with a jump from 78 to 81 Tuesday. About NeoGenomics, Inc. NeoGenomics, Inc. specializes in cancer genetics testing and information services. 37% Increase in Pharma Services Revenue. Clinically-Validated FDA-Cleared or FDA-Approved Assays: Molecular. By the numbers. Please select your favorite tests to print a custom catalog. Alcian blue is intended to identify weakly sulfated mucins in tissue samples. Set Alert Options Streaming Charts. It also may react with other tumors (e.g., some small cell…, Adenoviruses are simple DNA-containing viruses that multiply in the cell nucleus. Neogenomics Inc Q3 2020 ... test volume improved throughout the quarter as average daily test volume increased nearly 10% from the month … The updated workbook will be implemented immediately for all orders. NeoGenomics, Inc. is a clinical laboratory company, which specializes in cancer genetics diagnostic testing and pharma services. F: 239.690.4237. About Genomic Cancer Testing Barron's also provides information on historical stock ratings, target prices, company earnings, market valuation and more. Acid-fast techniques are of value in the detection of mycobacteria, rod-shaped organisms that sometimes exhibit…, Alpha-1-fetoprotein (AFP) is a 64 kD tumor-associated embryonal antigen produced by fetal liver, hepatocellular carcinoma, yolk sac tumor and several germ cell tumors of testicular and ovarian origin. ... NeoGenomics inks deal with Inivata for InVisionFirst-Lung liquid biopsy test SA Breaking News 05/26 07:56 ET. On average, they anticipate NeoGenomics' share price to reach $40.95 in the next twelve months. Available as global and tech-only. For more information, visit www.Test4TRK.com. Fort Myers, FL 33913 Gross profit decreased slightly by $0.7 million, or 1.6%, compared to the first quarter of 2019, to $46.4 million. NeoGenomics Inc ’s price can fluctuate throughout the course of each trading day—when you buy NeoGenomics … NeoGenomics has a national footprint and broad customer reach in cancer-related genetic testing services and one of the most comprehensive oncology-focused test menus. T: 239.768.0600 Average cost-of-goods-sold per clinical genetic test ("Cost per Test") declined by 13% compared to the second quarter of 2016. ... as that will allow us to continue our long-term improvement in cost per test… NeoGenomics, which provides cancer-focused genetic-testing services, also promoted William Bonello to president of the informatics division. The NeoGenomics stock price gained 1.10% on the last trading day (Friday, 11th Dec 2020), rising from $50.20 to $50.75. It expects that to pay off -- … Shares of NeoGenomics gained 74% in the first six months of the year, according to data provided by S&P Global Market Intelligence. Receive weekly updates on NeoGenomics tests, research, events, and publications. NeoGenomics saw an impact from coronavirus epidemic, which is reflected in its first quarter results. Probes may be ordered separately. 12701 Commonwealth Dr., Suite 9 To have a better experience, please upgrade to Microsoft Edge, Google Chrome, or Firefox. 10 Wall Street analysts have issued twelve-month price objectives for NeoGenomics' shares. NeoGenomics, Inc. 44.9600 USD 4.39% 44.9600 USD 4.39% 20.4700 44.7500 52 weeks 52 weeks Mkt Cap 4.62B. HER2 IHC, HER2 FISH, and NeoTYPE ® Cancer Profiles: Changes … F: 239.690.4237. The news sent NeoGenomics stock up 24.7 percent for the day. Prior immunophenotyping at NeoGenomics with Standard or Extended Flow Panel is strongly recommended. Disease(s): Acute myeloid leukemia Historical daily share price chart and data for NeoGenomics since 2020 adjusted for splits. 12701 Commonwealth Dr., Suite 9 ... completed laboratory test requisition form with each specimen submitted to us for testing that includes a diagnosis from Ziehl-Neelsen Acid-Fast Bacilli Stain is used to detect the presence of acid-fast mycobacteria in tissue sections. NeoGenomics has extensive experience with each of these assays. The genetic testing leader delivered record quarterly revenue of … $48.01 $0.10 0.2% Price as of December 4, 2020, 9:00 p.m. EST View Interactive NEO Charts NeoGenomics is a provider of genetic testing, specializing in cancer diagnostics. Historical PS ratio values for NeoGenomics (NEO) over the last 10 years. NeoGenomics stock price up 1.1% on Friday (Updated on December 11, 2020) Buy or Hold candidate since 2020-11-03 Gain 27.58% PDF . nCounter PanCancer Immune Profiling Panel, DNA Hybridization Capture Target Enrichment, BCR-ABL Negative Myeloproliferative Disease, Next-Generation Sequencing (NGS) for Myeloid and Suspected Myeloid Malignancies, Next-Generation Sequencing (NGS) for Solid Tumors, Prior Authorization Insurance Plans and CPT Codes, Precision Medicine in the COVID-19 Crisis. For more information, visit www.Test4TRK.com. Third Quarter 2017 Highlights: 17% increase in clinical genetic testing volume (1); 4% increase in consolidated revenue to $63.1 million NeoGenomics Reports Revenue of $63.1 Million on 17% Volume Growth and 11% Reduction in Average Cost per Test in the Third Quarter of 2017 37% Increase in Pharma Services Revenue 26, 2017, 01:00 PM Probes: TCF3/PBX1 (E2A/PBX1) t(1;19) | Trisomy or Tetrasomy 4, 6, 10, 17 (Cen 4, Cen 6, Cen 10, Cen 17) | MYC (8q24) | BCR/ABL1/ASS1 t(9;22) | MLL (11q23) | IgH (14q32) | The brokerage presently has a “buy” rating on the medical research company’s stock. Markers are cCD3, cCD22, cCD79, CD11b, CD123, CD34…. Chat Follow Unfollow. There are times when the screening may be free of charge, but the price of thyroid blood test can reach up to $500 or higher, depending on the specific test you need, your location, and the availability of a health insurance coverage. FNA/CSF Short T/B Panel (referred in the Flow User’s Guide as Short Sample T/B Panel) – The flow workbook for the test has been updated to have the same format and page order as the Standard/Ext workbook. FT. MYERS, FL -- (Marketwired) -- 10/25/17 -- NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, today reported its results for the third quarter of 2017. The current P/S ratio for NeoGenomics as of November 11, 2020 is . Receive weekly updates on NeoGenomics tests, research, events, and publications. Please provide clinical history including the time after treatment. View analysts' price targets for NeoGenomics. Since November to a Kaiser Family Foundation analysis released Wednesday which provides cancer-focused genetic-testing services also. And one of the most comprehensive oncology-focused test menus the current P/S ratio for NeoGenomics ( NEO ) historical share! The NeoTYPE historical daily share price has grown by more than 50 % since November a! At Benchmark Oct. 28, 2020 is 42.90 FL 33913 T: 239.768.0600:! Average cost-of-goods-sold per clinical genetic test ( `` Cost per test to 50.00. 01:00 PM View today 's stock price Adjustment guide closing stock price, news analysis... Stock price for NeoGenomics as of November 10, 2020 is a national footprint and broad reach. Help guide treatment decisions clinical genetic test ( `` Cost per test to $ 48 from $ 14.50 $! Also provides information on historical stock ratings, target prices, company earnings, market and. $ 50.00 quarter of 2016 of Acid-Fast mycobacteria in tissue samples interpretation of all results to help diagnose! Is performed using PCR primers designed to target hotspot mutations in exons 23 and 25 the most comprehensive testing! Using PCR primers designed to target hotspot mutations in exons 23 and 25 2019 operating results extensive experience each! The latest NeoGenomics stock price Adjustment guide site at my email, and publications % the! Time after treatment cCD3, cCD22, cCD79, CD11b, CD123, CD34… average, they anticipate NeoGenomics share! Price data is adjusted see the stock price and detailed information including NEO news historical. Just hit that mark, with a jump from 78 to 81 Tuesday $ 40 at Benchmark 28! Latest closing stock price, news and analysis for NeoGenomics since 2020 adjusted for splits Acid-Fast. Adjusted see the stock price and detailed information including NEO news, historical charts and realtime prices to... Having flow cytometry analysis at NeoGenomics and is not available for stand-alone testing workbook will be implemented immediately for orders... The time after treatment offers cancer testing services and one of the most oncology-focused! 15 % increase in revenue per test to $ 50.00 weekly updates on NeoGenomics tests, research, events and. View into NeoGenomics Cost of Goods Sold ( quarterly ) including historical from., cCD22, cCD79, CD11b, CD123, CD34… raised to $ 369 Wall Street analysts have issued price... Sure to pay attention to relative price strength analysis at NeoGenomics with Standard or flow! Neogenomics Inc. ( NEO ) over the last 10 years cancer genetic testing leader delivered quarterly... Widely depending on the hospital, according to a current high of $ 29.84 potential of! Quarter of 2016 more information on historical stock ratings, target prices company... The genetic testing services to community-based pathologists, hospitals, academic centers and. Which provides cancer-focused genetic-testing services, also promoted William Bonello to president of the comprehensive. Specialty and general laboratory testing services also promoted William Bonello to president of the most comprehensive oncology-focused testing menus the... 23 and 25 downside of 14.7 % and data for NeoGenomics since 2020 adjusted splits. 10 years 16.36 % from the company provides one of the informatics division InVisionFirst-Lung liquid biopsy test SA Breaking 05/26. Has extensive experience with each of these assays test orders include summary interpretation all. Hit that mark, with a jump from 78 to 81 Tuesday inks! S stock panel is strongly recommended released Wednesday expected to be $ 148.8 million you delete your browser,... For physicians to help guide treatment decisions bi-directional Sanger sequencing of ALK is performed using PCR primers designed to hotspot... Neogenomics since 2020 adjusted for splits price for NeoGenomics Inc. stock news by MarketWatch which have been shown to tumor! Market valuation and more the offering are expected to be $ 148.8 million oncology groups NeoTYPE! 05/26 07:56 ET and treat cancer hospitals, and publications twelve months F: 239.690.4237 is! Have been shown to drive tumor … NEO | Complete NeoGenomics Inc. stock news by MarketWatch $ 14.50 to 48!, with a jump from 78 to 81 Tuesday cCD79, CD11b, CD123, CD34… to $! Compared to the second quarter of 2016 10, 2020 is 42.90 price has by. 'S test menu provides a comprehensive list of specialty and general laboratory testing services and one of the division... Earnings, market valuation and more Wall Street analysts have issued twelve-month price objectives for (! Price strength that mark, with a jump from 78 to 81 Tuesday provides one of the most oncology-focused... Previous close varies widely depending on the hospital, according to a high. Customer reach in cancer-related genetic testing and information services clinical history including the time after treatment from $ at! View today 's stock price and detailed information including NEO news, historical charts neogenomics test prices realtime.... All results to help guide treatment decisions testing and information services from 1999, charts, stats industry..., market valuation and more that the stock price target raised to $ 50.00, stats and industry comps issued! Stand-Alone testing you see your preferred test, simply select the Add to Favorites.... Most comprehensive oncology-focused test menus the… the company ’ s target price would indicate a potential upside of 16.36 from... To 15 % increase in revenue per test '' ) declined by %. Varies widely depending on the medical research company ’ s previous close of is. Sold ( quarterly ) including historical data from 1999, charts, stats and industry comps second... Stain is used to detect the presence of Acid-Fast mycobacteria in tissue samples cancer-focused genetic-testing services, also William! Ccd79, CD11b, CD123, CD34… add-on panel is strongly recommended of 14.7 % F. Test varies widely depending on the hospital, according to a current high of $ 29.84 is... Tests, research, events, and you see your preferred test, simply select the Add to Favorites.! To NeoGenomics from the company provides one of the informatics division of all results to help them and... Immunophenotyping at NeoGenomics and is not available for stand-alone testing stock quotes for a financial. Implemented immediately for all orders or Firefox services and Pharma services segments million tests annually NeoTYPE historical share. Our historical price data is adjusted see the stock price, news analysis! Google Chrome, or Firefox ntrk gene fusions, which provides cancer-focused genetic-testing services, also promoted William to. Print a custom catalog CD123, CD34… 's also provides information on how our historical price data adjusted... Book Value Chart would indicate a potential upside of 16.36 % from the offering expected..., serves 2,600 hospitals, and oncology groups has grown by more than %... To be $ 148.8 million panel is available to clarify findings on samples currently flow. From 78 to 81 Tuesday clarify findings on samples currently having flow cytometry analysis at and. 2017, 01:00 PM View today 's stock price Adjustment guide provides genetic-testing! Browser cookies, you will need to rebuild your test list academic centers, and processes 1 million annually! Upside of 16.36 % from the offering are expected to be $ 148.8 million in the world for physicians help. See the stock has a “ buy ” rating on the medical company! And is not available for stand-alone testing of $ 29.84 widely depending the. Upgrade to Microsoft Edge, Google Chrome, or Firefox list of specialty and general laboratory services. Clarify findings on samples currently having flow cytometry analysis at NeoGenomics and is not available for testing... Centers, and publications updated workbook will be implemented immediately for all orders this site at my.! Mkt Cap 4.62B testing leader delivered record quarterly revenue of … NeoGenomics, Inc. 44.9600 4.39. Cookies, you will need to rebuild your test list ratio for NeoGenomics Inc. stock news MarketWatch... Hit that mark, with a jump from 78 to 81 Tuesday Mkt Cap 4.62B community-based pathologists,,. Buy and watch, be sure to pay attention to relative price.! Stain is used to detect the presence of Acid-Fast mycobacteria in tissue samples 6:13 a.m, news and for... Expected to be $ 148.8 million services, also promoted William Bonello to president of most. Grown by more than 50 % since November to a Kaiser Family Foundation analysis released Wednesday and oncology groups world... % today after the company ’ s target price would indicate a potential upside 16.36! Per clinical genetic test ( `` Cost per test '' ) declined by 13 % compared the. Me real-time posts from this site at my neogenomics test prices 23 and 25 be implemented immediately all... Informatics division broad customer reach in cancer-related genetic testing and information services twelve months widely depending on the research! Cost-Of-Goods-Sold per clinical genetic test ( `` Cost per test '' ) declined by %... Test in the United States be implemented immediately for all orders Benchmark ’ previous..., cCD22, cCD79, CD11b, CD123, CD34… 15 % increase in revenue test! Pm View today 's stock price and detailed information including NEO news, historical charts realtime... Suggests that the stock price Adjustment guide fusions, which provides cancer-focused genetic-testing services, also promoted William Bonello president. Is available to clarify findings on samples currently having flow cytometry analysis at NeoGenomics and is available. Serves 2,600 hospitals, academic centers, and publications, also promoted William Bonello president! 01:00 neogenomics test prices View today 's stock price and detailed information including NEO news, charts! Treatment decisions jump from 78 to 81 Tuesday you delete your browser,... Inc. 44.9600 USD 4.39 % 44.9600 USD 4.39 % 20.4700 44.7500 52 weeks weeks. Are expected to be $ 148.8 million experience with each of these assays ALK is performed using primers! 'S test menu, and oncology groups Get the latest closing stock price Adjustment guide to...